stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) EPS (diluted)
Haleon PLC Sponsored ADR's EPS (diluted) for fiscal 2025 was $0.49, up 22.5% from $0.40 in fiscal 2024. Over the past ten years it has ranged from $0.19 (fiscal 2019) to $0.49 (fiscal 2025) — the current reading is the highest in ten years. Haleon PLC Sponsored ADR ranks 20th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.49 | 22.50% |
| FY2024 | $0.40 | 42.86% |
| FY2023 | $0.28 | 0.00% |
| FY2022 | $0.28 | (31.71%) |
| FY2021 | $0.41 | 20.59% |
| FY2020 | $0.34 | 82.31% |
| FY2019 | $0.19 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2024 | $0.14 | 16.67% |
| Mar 2024 | $0.12 | 20.00% |
| Sep 2023 | $0.10 | 16.69% |
| Jun 2023 | $0.09 | (14.30%) |
| 1 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation compare | $26.50 |
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| ZTS Zoetis Inc. compare | $6.07 |
| TAK Takeda Pharmaceutical Co. compare | $0.66 |
| HLN Haleon PLC Sponsored ADR | $0.45 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $0.43 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on HLN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement